{"entity":{"id":"rilvegostomig","kind":"drug","name":"Rilvegostomig","aka":[],"tldr":"Rilvegostomig is an experimental bispecific antibody from AstraZeneca in phase 2 trials for non-small-cell lung cancer, aimed at PD-1 and TIGIT.","summary":"Rilvegostomig (AZD2936) is a bispecific antibody developed by AstraZeneca. Its targets are PD-1 and TIGIT (the sponsor names TIGIT x PD-1). The sponsor states: Rilvegostomig (AZD2936) is an anti-TIGIT/anti-PD-1 bispecific antibody given intravenously as monotherapy to enhance anti-tumour immune response in advanced/metastatic NSCLC with PD-L1 expression. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer. The largest, NCT04995523, plans to enrol 212 participants (actual) with primary completion was scheduled for 2026-08-28 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of Rilvegostomig","url":"https://clinicaltrials.gov/search?intr=Rilvegostomig"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":["pd1","tigit"],"drugs":[],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06692738","nct06564844","nct06989112","nct06921785","nct06357533","nct06627647","nct05775159","nct07098338","nct06996782","nct05123482","nct07115043","nct05489211","nct07720284","nct05702229","nct06764875","nct06467357","nct06109779","nct07431281","nct07069712","nct06868277","nct07221253","nct04995523"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"AZD2936","modality":"bispecific antibody","mechanism":"Rilvegostomig (AZD2936) is an anti-TIGIT/anti-PD-1 bispecific antibody given intravenously as monotherapy to enhance anti-tumour immune response in advanced/metastatic NSCLC with PD-L1 expression.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/rilvegostomig/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"},{"id":"tigit","kind":"target","name":"TIGIT","route":"/targets/tigit/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"},{"id":"compugen","kind":"company","name":"Compugen","route":"/companies/compugen/"}],"trial":[{"id":"nct06868277","kind":"trial","name":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer","route":"/trials/nct06868277/"},{"id":"nct06627647","kind":"trial","name":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous N","route":"/trials/nct06627647/"},{"id":"nct06692738","kind":"trial","name":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-s","route":"/trials/nct06692738/"},{"id":"nct05123482","kind":"trial","name":"A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies","route":"/trials/nct05123482/"},{"id":"nct06764875","kind":"trial","name":"A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer","route":"/trials/nct06764875/"},{"id":"nct06564844","kind":"trial","name":"A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following C","route":"/trials/nct06564844/"},{"id":"nct06996782","kind":"trial","name":"A Platform Study in Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct06996782/"},{"id":"nct04995523","kind":"trial","name":"A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC","route":"/trials/nct04995523/"},{"id":"nct07069712","kind":"trial","name":"A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma","route":"/trials/nct07069712/"},{"id":"nct07098338","kind":"trial","name":"A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct07098338/"},{"id":"nct07221253","kind":"trial","name":"A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)","route":"/trials/nct07221253/"},{"id":"nct07115043","kind":"trial","name":"A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors","route":"/trials/nct07115043/"},{"id":"nct07720284","kind":"trial","name":"An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC","route":"/trials/nct07720284/"},{"id":"nct06989112","kind":"trial","name":"DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC","route":"/trials/nct06989112/"},{"id":"nct05702229","kind":"trial","name":"Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","route":"/trials/nct05702229/"},{"id":"nct06467357","kind":"trial","name":"Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer","route":"/trials/nct06467357/"},{"id":"nct06921785","kind":"trial","name":"Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma","route":"/trials/nct06921785/"},{"id":"nct06357533","kind":"trial","name":"Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥","route":"/trials/nct06357533/"},{"id":"nct06109779","kind":"trial","name":"Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)","route":"/trials/nct06109779/"},{"id":"nct07431281","kind":"trial","name":"Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2","route":"/trials/nct07431281/"},{"id":"nct05489211","kind":"trial","name":"Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)","route":"/trials/nct05489211/"},{"id":"nct05775159","kind":"trial","name":"Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer","route":"/trials/nct05775159/"}],"roadmap":[{"id":"gallbladder-cancer-roadmap","kind":"roadmap","name":"Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials","route":"/roadmaps/gallbladder-cancer-roadmap/"}]}}